Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age1-18
SponsorChulalongkorn University
About this trial
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
Eligibility criteria
Qualifiers
Participants must have diffuse intrinsic pontine glioma at any timepoint following completion of standard radiotherapy
Age 1-18 years
Sex: Male or female
CNS reservoir catheter, such as an Ommaya or Rickham catheter, present in the proper location for CNS-directed therapy
Disqualifiers
Presence of >= grade 3 cardiac dysfunction or symptomatic arrythmia requiring intervention
Presence of primary immunodeficiency or bone marrow failure syndrome
Presence of clinical and/or radiographic evidence of impending herniation of CNS
Presence of > Grade 3 dysphagia
Trial design
Treatments tested in this trial
- B7H3 specific CAR T cell with IL-7Ra signaling domain
Treatment groups
9 Participants
are divided into 1 treatment groupSponsors and collaborators
Chulalongkorn University
Lead sponsor
King Chulalongkorn Memorial Hospital
Collaborator
Source ClinicalTrials.gov